Sequoia Financial Advisors LLC Purchases 1,487 Shares of United Therapeutics Corporation $UTHR

Sequoia Financial Advisors LLC raised its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 83.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,271 shares of the biotechnology company’s stock after purchasing an additional 1,487 shares during the period. Sequoia Financial Advisors LLC’s holdings in United Therapeutics were worth $1,594,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Torren Management LLC acquired a new position in shares of United Therapeutics during the 4th quarter worth $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares in the last quarter. WealthCollab LLC grew its position in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. grew its position in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB raised its stake in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $564.95, for a total transaction of $5,367,025.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,887,819.35. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $586.75, for a total transaction of $4,870,025.00. Following the transaction, the executive vice president owned 45,172 shares in the company, valued at approximately $26,504,671. This trade represents a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 482,155 shares of company stock valued at $266,844,149 in the last ninety days. 8.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research reports. Bank of America increased their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. HC Wainwright increased their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Raymond James Financial assumed coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Trading Up 0.9%

Shares of UTHR stock opened at $569.88 on Tuesday. The firm has a market capitalization of $24.19 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 1.80 and a beta of 0.60. The business’s 50-day moving average price is $552.09 and its 200-day moving average price is $503.34. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $6.63 EPS. On average, sell-side analysts predict that United Therapeutics Corporation will post 27.4 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.